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Object: Pancreatic cancer is one of the most lethal human cancer and appropriate experimental tumor
models are needed for the development of innovative therapeutic approaches. This paper describes an
experimental model of human pancreatic cancer and a related non invasive imaging technique suitable for
monitoring tumor growth and metastatization. The aim of the work was the implementation of an
experimental platform suitable for assessing the efﬁcacy of new therapeutic agents.
Materials and methods: Human pancreatic cancer cells (PANC-1-Luc+) were injected into the pancreas of
female athymic CD1 mice. Magnetic Resonance Imaging (MRI) at 4.7 T and Bioluminescence Imaging (BLI)
were performed in each mouse at three time points after cell inoculation (1, 2 and 3 months). Two groups
of mice were studied: the ﬁrst group of n = 13 mice in which 5 * 106 cells were injected and the second
group of n = 10mice in which 2 * 106 cells were injected. MRI examination included T2w acquisitions and
(at the last time point) Dynamic-contrast-enhanced-MRI (DCE-MRI).
Results: Each mouse underwent three longitudinal MRI and BLI examinations. BLI was more sensitive than
MRI producing higher detection rate at early time points. Moreover in one case of abdominal dissemination
of pancreatic tumor cells, small tumoral masses were detected by BLI and not detected byMRI. However BLI
appears more prone to experimental error most likely due to photon attenuation. In 4 mice BLI produced
false negative results. DCE-MRI experiments providing information on tumor perfusion were conducted
successfully in this anatomical district and demonstrated that the tumor tissues from the second
experimental group are more vascularized compared to the ﬁrst group.
Conclusion: The present study performed on the experimental model of pancreatic cancer here described
shows that MRI and BLI are complementary techniques and that synergistic application of both can
overcome the intrinsic limitations of each.
© 2015 Elsevier Inc. All rights reserved.1. Introduction
Pancreatic cancer is one of themost lethal human cancers with an
overall survival rate of 3%–5% and a median survival of less than
6 months. The short median survival is explained by the absence of
early symptoms and the lack of appropriate diagnostic tools for early
detection. The cancer’s lethal nature results from its propensity to+39 0458027613.
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ncreatic cancer growth
j.mri.2015.02.017usinrapidly disseminate to the lymphatic system and distant organs,
which occurs in more than 80% of cases. Metastasis to loco-regional
lymph nodes or distant organs is one of the major features of
pancreatic cancer and is typically already present at the time of
diagnosis. This aggressive biology and resistance to conventional and
targeted therapeutic agents lead to a typical clinical presentation of
incurable disease at the time of diagnosis, even nowadays. Despite
great efforts in recent years, conventional treatment approaches
have little impact on the course of this aggressive neoplasm [1].
Therefore, reproducible preclinical models are required to study the
underlying causes of tumor development, and the growth and
dissemination of pancreatic cancer. These models, as well as the
development of diagnostic imaging techniques to monitor tumor
growth and metastasis formation, would also be crucial for the
development of new and effective treatment modalities.g magnetic resonance and bioluminescence imaging, Magn Reson
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established [2]. The use of animal models in preclinical and basic
studies makes it possible to test diagnostic markers and drugs,
producing data that are more predictive of the distribution and
efﬁcacy of a compound [3]. In recent years new technologies have
become available for imaging small animals, and noninvasive
imaging in animal models has assumed increasing importance in
preclinical research, so that it is now an independent specialty [4,5].
These imaging modalities, which include Magnetic Resonance
Imaging (MRI), Computed Tomography (CT), Positron-Emission
Tomography (PET), Single Photon Emission Tomography (SPECT),
Optical Imaging (OI) and Ultrasound (US), have been utilized to
evaluate the pharmacologic activity of novel targeted therapies [6,7].
However, each of these imaging methods has distinct advantages
and limitations, and there are marked differences between their
detection sensitivity, spatial and temporal resolution. The use of
multiple imaging methods is therefore likely to provide comple-
mentary information on tumor biology [6,7] and response to
therapies. Recently Partecke et al. [5] have reported the application
of MRI to monitor the development of an orthotopic pancreatic
tumor model in mice. The present paper extends the approach
developed by Partecke et al. by adding Bioluminescence Imaging
(BLI) to the equation in order to further improve longitudinal
assessment of tumor evolution/regression.
It has been previously demonstrated that it is possible to select
Panc-1 sphere cells which are stem-like cells starting from Panc-1
adherent cell line [8]. Panc-1 sphere cells can mimic the stem-like
cell population in pancreatic cancer, but Panc-1 adherent cells may
be a more reliable model for preclinical applications [8].
In this study, an experimental model of orthotopic pancreatic
cancer was implemented by orthotopic injection of Panc-1 adherent
cells transfected with the gene reporter Luciferase (Luc). Tumor
development was studied over time using non-invasive imaging
techniques, namely Optical Imaging in the bioluminescence modal-
ity and Magnetic Resonance Imaging. Each technique showed
advantages and disadvantages that will be discussed. The aim of
this study was to deﬁne an experimental pancreatic tumor model
and suitable imaging modalities, to serve as experimental platform
for testing new therapeutic agents.
2. Materials and methods
2.1. Orthotopic human pancreatic xenografts in immunodeﬁcient mice
Experiments were carried out in compliance with national
regulations and were approved by the Ethics Committee of our
Institution. Human pancreatic cancer cell lines Panc-1-Luc+, were
kindly provided by Dr. Scott Kern (Departments of Surgery,
Pathology, and Oncology, The Johns Hopkins Medical Institutions,
Baltimore, MD, USA) and maintained under G418 selection. The
transfection procedure has been previously described [9]. Biolumi-
nescence activity of Panc-1-Luc + cells was tested before injection
in vivo.
Mice (female athymic CD1 mice, 4 weeks old, Charles River,
Lecco, Italy) were anesthetized using a ketamine/xylazine cocktail at
a ratio of 100 mg kg−1:20 mg kg−1. The abdominal skin was raised
with forceps and a 1-cm incision with sterile micro-scissors was
made slightly medial to the splenic silhouette. A second 1-cm
incision was extended into the abdominal cavity without injuring
the underlying organs. Using a pair of blunt-nose forceps, the tip of
the pancreatic tail was gently grasped and the pancreas/spleen was
externalized in the lateral direction, exposing the entire pancreatic
body and spleen. While gently retracting the pancreas laterally, a
needle was inserted into the tail of the pancreas and passed into the
pancreatic head region; cells, suspended in 60 μl of PBS containingPlease cite this article as: Ritelli R, et al, Pancreatic cancer growth usin
Imaging (2015), http://dx.doi.org/10.1016/j.mri.2015.02.0171% serum-free Matrigel (vol/vol), were slowly injected while
withdrawing the needle to the mid-body of the pancreas, forming
a ﬂuid-ﬁlled region within the pancreatic parenchyma. Then the
pancreas/spleen was internalized using blunt forceps and the
abdominal muscle layer was closed with continuous suture, while
the overlying skinwas closedwith a second set of interrupted suture.
The mice were divided into two groups: group n.1 included mice
(n = 13) injected with 5 * 106 Panc-1 Luc + cells, and group n.2
(n = 10) with 2 * 106 Panc-1 Luc + cells. Each animal was imaged
using BLI andMRI one, two and three months after cell injection. Prior
to BLI acquisition, the scarring at the level of the pancreaswas carefully
examined in order to assess the completion of wound healing.
2.2. Optical images acquisition and analysis
All the acquisitionswere performedusing the IVIS 200optical imager
(PerkinElmer, Hopkinton, MA, USA), equipped with a −90 °C cooled
camera sensor back-thinned, back-illuminated grade 1 CCD
2.7 × 2.7 cm, 2048 × 2048 pixels. The images were acquired in biolu-
minescence modality (without excitation lamps and without emission
ﬁlters) using the following parameters: Exposure time = 300 s;
Binning = 8; f/stop (diaphragmopening)=1;ﬁeld of view = 12.8 cm.
During luciferin injection and image acquisition, the mice were
keptundergaseous anesthesia (2%of isoﬂuraneand1 l/minof oxygen)
on the heated plate of the instrument. After a pre injection image,
which was acquired in order to assess the background emission,
luciferin was injected intraperitoneally (15 mg/mL in PBS, dose of
150 mg/kg, D-luciferin, Fireﬂy, potassium salt, 1.0 g/vial, Caliper Life
Sciences, Hopkinton,MA, USA). Then three post-injection imageswere
acquired at5, 10and15 min. Imageswere acquiredandanalyzedusing
Living Image 4.1 (PerkinElmer, Hopkinton, MA, USA). Measurements
were done in twoways. In theﬁrst one, Regions of Interest (ROIs)were
tracedmanually on the optical images in order to measure the photon
emission escaping from the animals’ skin in the abdominal location
within the selected ROI. In the second one, a threshold in the light
intensity was ﬁxed for all the images and the area with signal greater
than the threshold was measured.
2.3. MRI images acquisition and analysis
Mice were anesthetized by inhalation of a mixture of air and O2
containing 0.5%–1% isoﬂurane and placed in prone position inside a
3.5 cm i.d. transmitter–receiver birdcage coil. Images were acquired
using a Biospec Tomograph (Bruker, Karlsruhe, Germany) equipped
with a 4.7 T, 33 cm bore horizontal magnet (Oxford Ltd., Oxford,
United Kingdom). The imaging planes were coronal and transversal.
T2-weighted images were acquired using a T2w RARE sequence
with the following parameters. Coronal plane: TR = 4400 ms, TEeff =
67.2 ms, Field of view = 5.30 × 5.30 cm2, Matrix size = 256 × 256,
slice thickness = 1 mm, interslice distance = 1 mm. Transversal
plane: TR = 5000 ms, TEeff = 56 ms, Field of view: 5 × 2.5 cm2,
Matrix size: 256 × 128, slice thickness = 1 mm, interslice distance =
1 mm. The hyperintense region, relative to the surrounding tissues in
the speciﬁc anatomical region, was considered as tumor. In each
slice, the tumor region was manually delineated by using the
Region-of-Interest function of the software ParaVision 5.1 (Bruker,
Karlsruhe, Germany). Tumor volumes were quantiﬁed by multiplying
the number of tumor voxels by the individual voxel size. In the last
imaging session, Dynamic Contrast Enhancement (DCE-MRI) experi-
ments were also executed. Brieﬂy, T1w RARE images were acquired
before and at different time points after i.v. injection of the contrast
agent (Gd-DTPA, Magnevist, Schering, Germany) at a 100 μmol/kg
dosage. The parameters used were: TR = 733 ms, TEeff = 10.7 ms,
FOV = 3 × 3cm2, Matrix size = 256 × 128 zero ﬁlled at 256 × 256;
slice thickness = 0.75 mm, number of slices = 12. According tog magnetic resonance and bioluminescence imaging, Magn Reson
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images were acquired with a time resolution of 105 s. Three
regions-of-Interest (ROIs) were manually drawn to quantify the signal
in theexternal and internal part of the tumor and in theskeletalmuscle.
The external part of the tumor was considered as the strongly
enhancing region at the tumor periphery and corresponded in most
of tumors to a 2–3 mm wide band. The remaining area in the tumor
slice was considered as belonging to the internal ROI. DCE-MRI data
were quantiﬁed by calculating the Area-Under-the-Curve (AUC) of the
time dependence of the Signal Intensity Enhancement for the ﬁrst
10 min after contrast agent injection.
Both BLI and MRI images were independently analyzed by two
researchers (PB and RR) for the presence of tumor signal. In
discordant cases, a consensus reading was performed.2.4. Ex vivo histological and immunohistochemical analysis of
tumor xenografts
Threemonths after tumor induction,micewere sacriﬁced by cervical
dislocation for necropsy and tumor excision. After excision, tumor
masses were photographed and tumor diameters (d and D) were
measured by caliber. The tumor volumewas calculated according to the
formula: V = (d2 × D/2). Tumor samples were then formalin-ﬁxed,
embedded in parafﬁn, sectioned and de-parafﬁnized using xylene, and
hydrated by series of decreasing ethanol washes. Hematoxylin/Eosin
(H&E) staining was performed for each sample.3. Results
3.1. Sensitivity of BLI and MRI
Magnetic Resonance and BLI Images were acquired one, two and
threemonths after cell injection. Two researchers with experience in
MRI of experimental tumors evaluated tumor detectability in MR
images. The number of subjects in which tumors were detected is
shown in Table 1. In the ﬁrst group of mice (5 * 106cells) tumors
were detected in each mouse at one, two and three months after
injection using both MRI and BLI. At the ﬁrst time point only twelve
mice were imaged using BLI because of experimental problems.
Moreover, at the third time point, data relative to only twelve mice
are presented because one mouse was sacriﬁced two months after
cell injection due to excessive tumor growth and intestinal invasion
(see Fig. 3).
In the second group of mice (2 * 106cells) tumors were not
detectable in a great number of animals, especially at the ﬁrst time
point. In this group, BLI detectedmore tumors thanMRI at early time
points, but with the increase in tumor size, MRI proved to be as
sensitive as BLI. Moreover BLI detection of tumor was prone to
experimental errors, because in n = 4 mice belonging to the second
experimental group, tumors were detected at a given time point and
not detected at the following time point (false negative). It is
worthwhile to mention that false negative response is easily due to
misinjection of luciferin into the intestinal tract rather than i.p. and
by repeating the injection this issue could be eliminated.Table 1
Sensitivity of OI and MRI techniques.
Experiment 1st month 2nd month 3rd month
MRI (5 * 106 cells) 13/13 13/13 12/12
OI (5 * 106 cells) 12/12 13/13 12/12
MRI (2 * 106 cells) 3/10 6/10 8/10
OI (2 * 106 cells) 5/10 7/10 8/10
Data are reported as thenumber of tumors detected over the number of subjects imaged.
Please cite this article as: Ritelli R, et al, Pancreatic cancer growth usin
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Representative BLI and MRI images acquired in a mouse belonging
to experimental group n.1 are shown in Fig. 1. Fig. 1g and h shows the
timeevolutionof average tumor sizemeasuredbyMRIwhile Fig. 1i and
j shows results obtained by BLI; data are reported asmean ± SEM. The
MRI readout of tumor size is represented by tumor volume expressed
in mm3while the BLI readout is represented by the light ﬂux (number
of photons/s). Both techniques showed that tumor size increasedmore
rapidly in theﬁrst group than in the secondone. In experimental group
n.2, tumor volumes at MRI were about ten times smaller than in
experimental group n.1 and, especially at the ﬁrst time point, were
determined with considerable uncertainty due to the small size of the
tumors themselves and the confounding effect of abdominal struc-
tures. This contributed to the low detection rate of tumors in this
experimental group.
In BLI data from animals belonging to experimental group n.2 we
observed wide variability of tumor size (unlike MRI data from the
same group). This variability was partly due to the smaller number of
data available in this group, since some animals were excluded
(n = 4) because no emission was detected.
In some mice (belonging mainly to experimental group n.2) we
found a non-monotonic trend: photon ﬂux measured two months
after cell injectionwas higher than the valuemeasured threemonths
after. This ﬁnding is in contrast with the volume measured using
MRI, which showed a monotonic increasing trend over time in each
animal (see graphical insert in Fig. 1).
3.3. Correlation between MRI and BLI
We investigated the correlation between the MRI-determined
tumor volume and BLI signal in the ﬁrst group of animals (5 * 106
cells). Results are reported in Table 2 as correlation coefﬁcients of the
assumed linear relationship. There was a good linear correlation
between MRI and BLI photon ﬂux when correlating all time points.
This correlation worsens when each time point is analyzed
separately. At the ﬁrst and second time point there is low or no
correlation at all (data not shown), while at the third time point a
good linear correlation was obtained.
Following Bouvet et al. [12], the correlation between the MRI
volume and the BLI area was also analyzed. As shown in Table 2, the
correlation between MRI and BLI data improved when BLI area is
considered instead of photon ﬂux. For the last time point (three
months, Table 2 c, d) the correlation coefﬁcient, R2, was substantially
higherwhencorrelatingBLI areavs.MRI volume thanwhen correlating
BLI ﬂux vs. MRI volume. In the ﬁrst case, analyzing all mice observed at
the third time point alone, an R2 value equal to 0.82 was obtained
(Table 2c). The correlation between MRI/BLI readouts and the tumor
volumes as determined by ex vivo measurements was then investi-
gated. Results are shown in the last three columns of Table 2 and are
obviously restricted to the last time point (c and d lines). A very good
correlation was detected between ex vivo and MRI determined tumor
volumes, while the correlationwith BLI readouts was poor. Among the
two considered BLI readouts, the BLI area was correlated to ex vivo
tumor volumes better than photon ﬂux.
In the second group of animals (2 * 106 cells) the correlation
between MRI and BLI was substantially lower than in the ﬁrst group,
a correlation coefﬁcient R2 = 0.51 was obtained by including in the
analysis all mice in which tumors were detected by both techniques
at the different time points.
3.4. DCE-MRI
Dynamic Contrast Enhancement MRI (DCE-MRI) experiments
were performed in both experimental groups at the last time point.g magnetic resonance and bioluminescence imaging, Magn Reson
Fig. 1. BLI and MRI in the longitudinal investigation of tumor growth. Representative Bioluminescence (a, b and c) and MR (d, e and f) images acquired in a subject belonging to
experimental group n.1 at 1, 2 and 3 months after cell injection. Color bar reports photon ﬂux expressed as (number of photons)/s/cm2/sr. The arrows in panels d–f indicate the
tumor mass. Panels g, h, i and j show the time dependence of tumor size assessed using MRI and BLI in the two experimental groups. Panels g and i present data from the ﬁrs
group of animals as obtained with MRI and OI respectively. Panels h and j present data from the second group of animals. In the insert individual size data are shown on a
logarithmic scale.
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Table 2
Correlation coefﬁcient (R2) among MRI, BLI and ex vivo determination of tumo
volumes in the experimental group n.1.
R2 MRI vol vs.
photon ﬂuxes
MRI vol vs.
BLI areas
Ex vivo vol
vs. MRI vol
Ex vivo vol vs.
photon ﬂux
Ex vivo vol vs
BLI area
a 0.68 0.72 / / /
b 0.69 0.77 / / /
c 0.61 0.82 0.98 0.57 0.76
d 0.55 0.76 0.98 0.49 0.66
We considered 4 sub-groups of animals: a) all mice, all time points; b) only mice tha
showed a monotonic increasing trend of photon ﬂuxes, all time points; c) all mice
third time point only; d) only those mice that featured a monotonic growth (third
time point only). Photon Fluxes and BLI Areas are relative to quantitative value
extracted from bioluminescence images. In the ﬁrst case the photon ﬂux in a selected
ROI was measured. In the second case the area of the region in the image in which the
photon ﬂux was higher than a selected threshold was measured.
Fig. 2. DCE-MRI experiment: representative images and time course of the signal.
contrast agent injection. b) T1 weighted image acquired immediately after contrast ag
internal part of the tumor and in the skeletal muscle. d) Time dependence of the sig
periphery (outer tumor), in the tumor core (inner tumor) and in skeletal muscle (m
one animal belonging to the group n.2. The time course of the signal intensity for
compared to group n.1. Outer tumor andmuscle show similar behavior with respect t
used as external standard to normalize the signal intensity during acquisition.
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t
,
sT1w images were acquired before and, dynamically, after injection of
Gd-DTPA at the clinical dosage of 100 μmol/kg. Fig. 2 shows
representative T1w, axial images acquired before (Fig. 2a) and
immediately after injection of Gd-DTPA (Fig. 2b) in amouse belonging
to experimental group n.1. Fig. 2c shows positioning of ROIs used to
evaluate AUC in the external and internal part of the tumor and in the
skeletal muscle. Fig. 2d and e shows the time dependence of signal
intensity (SI, normalized to the signal intensity before contrast agent
injection) in the three Regions of Interest (ROIs), for representative
animals belonging to the experimental group n.1 and n.2, respectively.
In both groups, the time dependence of SI clearly discriminates
between external and internal regions of the tumor. The time course ofa) T1
ent in
nal int
uscle)
group
o grou
usinthe signal intensity for group n.2 clearly shows faster response to
contrast agent in the core of the tumor when compared to group n.1.
Outer tumor and muscle show similar behavior with respect to group
n.1. For both groups, in the external region, SI shows a faster and larger
increase than in the internal ROI; this corresponds to the presence of
highly vascularized tissue generally observed in the external part of
xenografts in comparison to the internal part [10,11]. It is worthwhile
to mention that the experimental observation of differential vascular-
ization between internal and external region of the tumor, commonly
observed also in other xenograft tumor models as for example colon
carcinoma [10,11], does not mean that the present experimental
model is highly vascularized as these other models are. The
enhancement of the SI is in fact strongly dependent on several
acquisition parameters, including acquisition sequence and its timing
contrast agent and dosage ﬁeld strength, which should be carefully
checked in order to perform a similar comparison. DCE-MRI curves
were quantitatively analyzed using the Area-Under-the-Curve (AUC)
[10]. Two ROIs were included in the analysis: one ROI was manually
drawn to cover all tumor tissue and a second ROI was placed over
skeletal muscle. The AUC values (in the time interval 0–10 min after
contrast agent injection) were calculated for both tumor and muscle
tissues. In experimental group n.1, the average AUC (normalized to
muscle) amounted to 1.92 ± 0.63 (mean ± SD), which was signiﬁ-
cantly lower than in group n.2 (AUC = 2.9 ± 0.74). AUC values
provide direct information about the vascularization of the tissues,
showing that the tumor tissues from experimental group n.2 (2 * 106
cells) are more vascularized. This is probably due to the larger average
size reached by tumors in experimental groupn.1,which is in linewith
thewell-known feature of xenografts of beingmore vascularized at the
tumor periphery [13].weighted image acquired in one animal belonging to experimental group n.1 before
jection. c) Image showing positioning of ROIs used to evaluate AUC in the external and
ensity, normalized to pre contrast value, as a function of time (minutes) in the tumor
for one animal belonging to group n.1. e) Time dependence of the signal intensity for
n.2 clearly shows faster response to contrast agent in the core of the tumor when
p n.1. The high intensity object in the lower left corner of images is a Gd-DTPA solution
g magnetic resonance and bioluminescence imaging, Magn Reson
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One mouse belonging to experimental group n.1 featured bowel
tumor masses clearly detected by BLI but not by MRI. Images are
shown in Fig. 3. One month after cell injection (Fig. 3a, on the left)
weak bioluminescence was detectable both on the left and right
sides of the abdomen. Twomonths after cell injection (Fig. 3a, on the
right) several spots were detectable on the left side of the abdomen,
in addition to themassive emission coming from the right part of the
abdomen corresponding to the primary tumor. Fig. 3c and d shows
coronal and transversal contiguous T2w MRI slices acquired two
months after cell injection. While the primary tumor is clearly
visible, no evidence of intestinal invasion is apparent. At necropsy
the presence of small masses in the intestine (about 3 mm in
diameters) was conﬁrmed (see arrows in Fig. 3b). H&E staining
conﬁrmed that small masses excised from this subject were
composed of tumor cells. The third month data are not available
because the mouse had already been sacriﬁced.
3.6. Histology
After the third time point of acquisition all mice were sacriﬁced
by cervical dislocation at the end of the last images data capture.
During the necropsy, liver as well as the whole abdominal and
thoracic cavities were carefully observed in order to detect potential
tumor diffusion by macroscopic analysis. In a single animal,
intestinal tumor masses were detected that indeed were alsoig. 3. Visualization of small bowel tumor masses. a) Optical Images acquired one (on the left) and two (on the right) months after cell injection. Color bar reports photon ﬂux
xpressed as (number of photons)/s/cm2/sr.; b) macroscopic ﬁndings after sacriﬁce show small masses (arrows) in the small intestine; c) T2wMR images acquired in the corona
lane and d) in the axial plane show the clearly detectable primary tumor (indicated by arrows) but not bowel tumor masses.F
e
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analysis, primary tumors, spleen, residual normal pancreas and small
intestine were excised for histology [14]. Fig. 4 reports macroscopic
and histological images in representative animals. Fig. 4b shows H&E
staining of a tumor mass excised from a mouse belonging to the
group n.1 in which both imaging techniques revealed the tumor.
H&E staining conﬁrmed that the excised mass from this mouse was
composed by tumor cells: the high number and morphological
aspects of cells and the high degree of mitosis were important
indicators of the tumor tissue. Moreover no evident signs of necrosis
were detected. Fig. 4c shows the pancreas extracted from one animal
belonging to the group n.2 in which neither MRI nor BLI detected
tumor signal. In this case, H&E clearly shows normal pancreatic
tissue.
In the lower line of Fig. 4 we report H&E staining of small masses
collected from the small intestine of the only mouse that showed
bowel tumor masses. H&E staining conﬁrmed that these masses
were tumor tissues.
4. Discussion
Reproducible preclinical models, as well as optimization of
imaging techniques for monitoring tumor growth and metastasis
formation, are crucial for the development of new and effective
treatment modalities. Currently, several mouse models of pancreatic
cancer have been established [15,5]. These include subcutaneously
[16,17] and/or orthotopically [18,19] implanted xenografts of humang magnetic resonance and bioluminescence imaging, Magn Resonl
Fig. 4. Ex vivo and histological examinations. a) Photos of tumors excised from representative animals belonging to the group n.1. b) H&E staining of a tumor mass excised from a
mouse belonging to the group n.1 in which both imaging techniques revealed the tumor. H&E staining conﬁrmed that the excised mass from this mouse was composed by tumor
cells. c) Pancreas and spleen extracted from one animal belonging to the group n.2 in which neither MRI nor BLI detected tumor signal. In this case, H&E clearly shows normal
pancreatic tissue. d) H&E staining of masses collected from the small intestine of the only mouse that showed bowel tumor masses. H&E staining conﬁrmed that these masses
were tumor tissues.
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In this study we focused on the behavior of Panc-1-Luc + cells when
injected into the pancreas of nude mice. Because orthotopically
implanted tumors grow deep within the abdomen, non-invasive
imaging methods to assess their growth rate and potential
dissemination over time are needed [12]. In this paper we used
and compared optical imaging in the bioluminescence modality
(BLI) with MRI.
First of all, we addressed the sensitivity of the two modalities.
Two experimental groups were investigated in which tumors were
induced by injecting 5 * 106 and 2 * 106 cells respectively. In the ﬁrst
group, as expected, tumors reached larger sizes and were detected
with same sensitivity by both techniques. In the second group,
characterized by smaller sizes, MRI proved less sensitive than BLI at
the ﬁrst time point. However MRI sensitivity increased up to 80%
3 months after injection.
Our results show that BLI is more sensitive thanMRI in the case of
the small tumors, and also in the detection of small bowel tumor
masses where MRI failed. In fact one mouse displayed small light
spots all over the abdomen while MRI only detected the main tumor
mass (Fig. 3). At necropsy and histology, small masses were found
throughout the bowel, which were conﬁrmed to be tumor tissues.
In addition to sensitivity, a reliable in vivo imaging technique
needs to meet the requirement of consistency of data. In the absence
of therapeutic treatment, the tumor mass is expected to monoton-
ically increase over time. This was observed in each subject using
MRI, but not using BLI, which is a somewhat surprising ﬁnding.
Simple T2w MRI cannot discriminate between viable and necrotic
tumor tissue and one possible explanation for the above-mentioned
ﬁnding could be the fact that, as MRI-detected tumor volume
increases, the viable tumor mass detected by BLI may actually
decrease. However we are inclined to exclude this possibility
because histology did not indicate substantial necrotic areas, andPlease cite this article as: Ritelli R, et al, Pancreatic cancer growth usin
Imaging (2015), http://dx.doi.org/10.1016/j.mri.2015.02.017also because this non-monotonic trend was mainly observed in
experimental group n.2, characterized by tumors having smaller
volumes and higher perfusion than those in group n.1. As mentioned
before, photon attenuation from different depth of abdominal tissues
could justify this ﬁnding. Other explanations for the observed signal
attenuation in the middle time point could be the luciferin batch or
scarce tumor perfusion, at this time point, that could partially
prevent luciferin delivery to tumor cells. A similar non-monotonic
trend of tumor BLI signal over time has been reported in one study of
brain tumors [20]. In this study the authors used BLI and observed
some animals with spontaneous regression of BLI signal but not of
MRI volume. The authors stressed the potential confounding effect of
similar subjects in any preclinical therapeutic response trials, and the
value of using BLI and MRI in combination. Moreover other papers
reported that the intensity of in vivo BLI signal strongly depends on
the depth of the light source due to strong attenuation by overlying
tissue [21].
In general, BLI signals have been found to correlate well with MRI
measurements of tumor volumes (see Table 2). As far as experi-
mental group n.1 is concerned, we can ﬁnd a good correlation
between MRI volumes and BLI photon ﬂuxes, especially when we
include in the analysis all acquisitions performed at the three time
points. If we separately analyze all the data obtained 1, 2 and
3 months after cell inoculation, a good correlation is found only at
the third time point. In experimental group n.2 the correlation
between MRI and BLI was worst probably due to the smaller sizes of
tumors corresponding to a smaller photon ﬂux and also to a reduced
number of animals.When BLI andMRI readouts were comparedwith
ex vivo determined tumor volume, MRI was found to correlate better
than BLI with ex-vivo values.
A poor correlation between BLI data and MRI/histology tumor
volume has been reported in an experimental model of bladder
cancer xenografts [22]. Interestingly, the correlationwas poor in KU7g magnetic resonance and bioluminescence imaging, Magn Reson
8 R. Ritelli et al. / Magnetic Resonance Imaging xxx (2015) xxx–xxxxenografts, but good in 253JB-V xenografts. The second cell line
produced tumors characterized by homogeneous distribution of
vessels while the ﬁrst produced tumors with necrotic core, vessels
distributed in the tumor periphery [22] and hypoxic regions. These
ﬁndings underline the importance of hypoxia and luciferin delivery
to the tumor [22].
BLI is better than MRI when the aim is to detect small tumors, but
showsproblemsof consistency asdemonstrated by thenonmonotonic
growthof the tumorphotonﬂuxes asMRI-measuredvolumes increase.
The variability of the tumor depth, leading to different absorption of
photons, was probably the main cause of this erratic performance. On
the other hand MRI shows a complementary pattern: it misses the
smallest tumors but features great consistency over time and a
monotonic trend with time elapsed after cell injection.
Moreover, DCE-MRI experiments could easily be conducted in
this anatomical district. DCE-MRI provided us information about the
vascularization of tumor masses, showing differences between the
two groups of animals (tumors in group n.2 being more vascularized
than in group n.1) and differences between external and internal
regions of a given tumor. The external region was more vascularized
than the internal one, which was in line with ﬁndings in other
experimental models [13,23]. Moreover, since the enhancement of
tumor tissue was higher than the enhancement of surrounding
tissues, muscle and abdominal organs, it could help identiﬁcation of
tumor masses when the tumor is small.
Nowadays, luciferase transfected cell lines are extensively used
for cancer models to assess in vivo growth, metastatic potential and
response to therapies non-invasively by BLI. However, the possibility
that luciferase-expression is associated with altered cell growth in
vivo has been investigated in the literature with contradictory
results [24]. In the present work this point has not been investigated
because the focus was the comparison of two imaging modalities
using a single cell line.
5. Conclusion
In conclusion, MRI and OI are two complementary techniques for
in vivo imaging, both targeting crucial features of tumor develop-
ment. In particular this study demonstrates that a bimodal approach
combining MRI and BLI is necessary when developing an experi-
mental platform for testing the efﬁcacy of new therapeutic agents.
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